citric acid; gluconolactone; magnesium carbonate: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
United Guardian	RENACIDIN	citric acid; gluconolactone; magnesium carbonate	SOLUTION;IRRIGATION	019481	NDA	United-Guardian, Inc.	0327-0012-30	30 BOTTLE in 1 CARTON (0327-0012-30) / 30 mL in 1 BOTTLE	2016-02-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: June 2, 2026

The supplier market for the excipients citric acid, gluconolactone, and magnesium carbonate is fragmented across global chemical producers and specialty excipient distributors. For procurement and formulation, the key decision points are grade (food/pharma, BP/USP/EP), spec compliance (assay, heavy metals, residual solvents, microbial limits), particle size and solubility profile (where relevant), and whether customers can support regulatory submissions (DMF/CoA, audit cadence, change-control traceability).

This market view is built around the largest recurring industrial and pharma-grade sources, plus the typical channel partners that distribute compliant lots into pharmaceutical and dietary supplement customers.

Who supplies pharmaceutical-grade citric acid and what grades matter for pharma formulations?

Citric acid is supplied at scale by global chemical makers and by excipient distributors that break down volumes and certify compliance to pharmacopeial standards. In pharma, procurement typically targets USP/EP/BP citric acid monohydrate or anhydrous citric acid, with controlled impurities (heavy metals, sulfate/oxalate, microbial limits where required).

Which companies supply citric acid used as a pharmaceutical excipient?

Commonly sourced manufacturers and major industrial suppliers include:

Zhejiang NHU Co., Ltd. (China) – large-volume citric acid producer used across food, pharma, and technical grades.
CJ CheilJedang (South Korea) – biosourced citric acid supply for food and industrial excipient markets.
MITSUI Chemicals / joint supply networks (Japan, via industry partners) – citric acid is commonly available through Japanese and regional distributors serving pharma.
Vertellus / BASF-adjacent distribution networks (Europe, via distributors) – pharma-certified citric acid is often sourced through excipient channels rather than direct chemical contracting.
Prayon S.A. (Belgium) – not a dominant citric acid maker per se, but frequently appears as part of European excipient supply chains for related acids and salts, depending on distributor portfolio.
Corbion (Netherlands) – supplies citric acid as part of broader fermentation-based ingredients ecosystem in some channels.

(For direct contracting in the pharma channel, most buyers source via excipient distributors that provide specific documentation packages and batch traceability tied to pharmacopeial monographs.)

What citric acid forms are typically specified in pharmaceutical purchases?

Citric acid monohydrate
Citric acid anhydrous
“USP/FCC/EP grade” designations (often supported by CoA and compliance statements)

What quality specs do pharma buyers typically require?

Assay (citric acid content)
Heavy metals (as Pb, As, Cd, Hg)
Sulfated ash / sulfate content
Oxalate
Microbial limits (if used in products with microbial control requirements)
Particle size and bulk density (where directly affecting blending and uniformity)

Which supply-channel structure is most common?

Direct from a large chemical manufacturer when volumes are high and change-control is manageable.
Through an excipient distributor (full documentation, faster allocation, batch-level traceability) when regulatory submissions and qualification matter more than unit cost.

Who supplies pharmaceutical-grade gluconolactone and what is the sourcing risk profile?

Gluconolactone is more specialized than citric acid. It is used in pharmaceutical and nutraceutical formulations for acidulant and chelating/complexing functionality. Supply tends to concentrate among chemical and fermentation-product producers plus regional excipient distributors.

Which companies supply gluconolactone for pharma and supplement use?

The principal supplier categories are:

Specialty fermentation and fine-chemical producers that make gluconolactone from glucose via fermentation and downstream conversion
Global excipient distributors that stock and certify gluconolactone to pharmacopeial or specification targets depending on customer requirements

In practice, sourcing is often done through excipient distributors due to:

documentation demands (CoA, compliance to monographs, audit-ready quality systems)
batch traceability
shorter lead times for lot allocation

What grade and monograph compliance is usually requested?

USP/EP/BP compliant gluconolactone (or internal specification equivalent)
Material is commonly supplied as a white crystalline powder (typical appearance category)

What quality issues drive vendor qualification?

Residual sugars and related impurities
Specific purity limits (heavy metals, loss on drying)
Microbial and endotoxin-related limits when used in sterile adjacent or sensitive products
Moisture control for blending reproducibility

How concentrated is the supplier base relative to citric acid?

Gluconolactone generally has fewer “true” direct chemical makers than citric acid at the consumer level, which increases:

allocation and spot-price movement risk
single-source risk if a formula relies on one distributor-managed lot

Who supplies magnesium carbonate for pharmaceutical excipient use and what specs should procurement demand?

Magnesium carbonate is used as an antacid/excipient, buffering agent, and in some formulations for handling pH and stability. Procurement frequently requires compliance to pharmacopoeias and tight impurity constraints because magnesium salts can carry variable heavy metal profiles depending on source ore or refining stream.

Which companies supply magnesium carbonate for pharma?

Magnesium carbonate is supplied by:

Mineral processing and magnesium chemical manufacturers
Inorganic excipient producers
Excipient distributors providing pharma documentation and consistent grades

Typical supply routes:

direct from inorganic chemical producers for large-volume commercial manufacture
through distributors for pharma-lot traceability and shorter lead times

What magnesium carbonate attributes matter most in pharma purchasing?

Pharmacopeial monograph compliance (USP/EP/BP grade)
Particle size distribution and surface area (affects compaction, dispersion, and taste)
Assay (Mg content or MgCO3 content depending on spec)
Heavy metals (As, Pb, Cd, Hg)
Chloride/sulfate limits
Loss on ignition (reflects carbonate content and moisture)

What change-control issues show up in magnesium carbonate sourcing?

mineral source changes that shift:
- particle size
- trace impurity profile
- calcination and drying history
physical property drift that can change blend behavior and tablet/capsule uniformity

How do excipient distributors vs direct chemical producers change availability for citric acid, gluconolactone, and magnesium carbonate?

Typical distributor portfolio patterns

Distributors stock common excipients (citric acid) at scale.
Distributors often manage the “pharma compliance layer” for gluconolactone and magnesium carbonate through:
- batch documentation
- audit-ready quality systems
- consistent pack sizes for formulation development

Procurement trade-offs

Direct chemical producers:
- advantage: cost and scale
- disadvantage: documentation and change-control burden
Distributors:
- advantage: faster allocation, lot-level traceability, regulatory-ready paperwork
- disadvantage: pricing and availability tied to distributor allocations and market cycles

What procurement spec package should be aligned for all three excipients to avoid regulatory friction?

Use a consistent vendor qualification envelope across:

CoA content (assay, impurities, heavy metals, microbial where applicable)
Material specification (pharmacopeial monograph mapping)
Regulatory support (where DMFs or letters of access are used, if applicable)
Change-control (site changes, processing changes, impurity trend reporting)
Supply chain traceability (batch trace-back and retest policies)

For these excipients, the most common failure modes in qualification are impurity drift and failure to meet specific pharmacopeial or internal limits under stability and blending conditions.

Which supplier selection criteria most affect long-term continuity for citric acid, gluconolactone, and magnesium carbonate?

Continuity KPI checklist

manufacturing site stability and audit history
multi-source availability for each excipient grade
ability to provide batch-specific compliance data quickly
documented process robustness and impurity control systems
packaging control (moisture barrier where relevant)

Operational KPI checklist

lead time under allocation stress
variability in physical properties affecting granulation and blending
retest window practices and quarantine policies

Key Takeaways

Citric acid is broadly supplied globally; pharma-grade access is usually easy via major chemical makers or excipient distributors with USP/EP-aligned documentation.
Gluconolactone is more specialized and typically requires tighter vendor qualification because supply concentration is higher and impurity sensitivity is greater.
Magnesium carbonate supply is usually accessible, but physical property drift and impurity profile variation can materially affect formulation performance and regulatory acceptance.
Distributor vs direct sourcing is a primary decision variable: distributors reduce documentation friction; direct suppliers reduce unit cost and can improve supply leverage at scale.

FAQs

What USP/EP grades of citric acid are most commonly used in solid oral formulations?
How do gluconolactone impurity profiles affect stability and compatibility in drug product formulations?
What particle size controls matter most for magnesium carbonate in tablet and powder blends?
What documentation should procurement require to support regulatory filings for these excipients?
What multi-sourcing strategy reduces allocation risk for gluconolactone and magnesium carbonate?

References

USP-NF (citric acid monograph; magnesium carbonate monograph; gluconolactone monograph). U.S. Pharmacopeia.
EP Monographs (citric acid; magnesium carbonate; gluconolactone). European Directorate for the Quality of Medicines and HealthCare.
BP Monographs (citric acid; magnesium carbonate). British Pharmacopoeia.

Suppliers and packagers for generic pharmaceutical drug: citric acid; gluconolactone; magnesium carbonate